News
07-26-2012, 09:11 PM
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, noted today that individual site, investigator-initiated results of an ongoing Phase 3 clinical trial of 99m-Tc-Tilmanocept (Lymphoseek) were presented at the American Head and Neck Society's 8th International Conference on Head and Neck Cancer (ICHNC), held in Toronto, July 21-25, 2012.
More... (http://www.news-medical.net/news/20120727/Navidea-announces-results-from-Lymphoseek-Phase-3-trial-on-head-and-neck-squamous-cell-carcinoma.aspx)
More... (http://www.news-medical.net/news/20120727/Navidea-announces-results-from-Lymphoseek-Phase-3-trial-on-head-and-neck-squamous-cell-carcinoma.aspx)